First Horizon Advisors’s Pacific Biosciences PACB Stock Holding History

First Horizon Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$3.53K	Sell	2,850 -1,547	-35%	-$1.79K	﹤0.01%	1916
2025 Q1	$5.19K	Sell	4,397 -580	-12%	-$890	﹤0.01%	1798
2024 Q4	$9.11K	Buy	4,977 +178	+4%	+$347	﹤0.01%	1639
2024 Q3	$8.16K	Sell	4,799 -151	-3%	-$248	﹤0.01%	1674
2024 Q2	$6.78K	Hold	4,950	–	–	﹤0.01%	1676
2024 Q1	$18.6K	Buy	4,950 +778	+19%	+$4.55K	﹤0.01%	1363
2023 Q4	$40.9K	Buy	4,172 +724	+21%	+$5.92K	﹤0.01%	1032
2023 Q3	$28.8K	Sell	3,448 -1,192	-26%	-$13.6K	﹤0.01%	1100
2023 Q2	$61.7K	Sell	4,640 -298	-6%	-$3.62K	﹤0.01%	796
2023 Q1	$57.2K	Buy	4,938 +386	+8%	+$3.84K	﹤0.01%	829
2022 Q4	$37.2K	Buy	4,552 +603	+15%	+$5.2K	﹤0.01%	980
2022 Q3	$22K	Buy	3,949 +903	+30%	+$5.18K	﹤0.01%	1203
2022 Q2	$13K	Buy	+3,046	New	+$18.5K	﹤0.01%	1478
2022 Q1	–	Sell	-1,283	Closed	-$25K	–	2131
2021 Q4	$25K	Buy	+1,283	New	+$31K	﹤0.01%	1194

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Horizon Advisors's PACB Position: Q2 2025 in Review

First Horizon Advisors reduced its Pacific Biosciences (PACB) stake by 35% in Q2 2025, selling an estimated $1.79K and leaving 2,850 shares worth $3.53K. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

First Horizon Advisors first reported a position in PACB in Q4 2021 and has held it in 14 quarters since. The position peaked at $61.7K in Q2 2023. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

First Horizon Advisors held 2,850 shares of Pacific Biosciences worth $3.53K as of Q2 2025.
First Horizon Advisors sold 1,547 Pacific Biosciences shares in Q2 2025, an estimated $1.79K.
Pacific Biosciences made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1916 holding.
First Horizon Advisors first reported a position in Pacific Biosciences in Q4 2021 and has held it in 14 quarters since.
First Horizon Advisors's Pacific Biosciences position peaked at $61.7K in Q2 2023.
207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.